United States securities and exchange commission logo





                            September 22, 2021

       Martin Lehr
       Chief Executive Officer
       Context Therapeutics Inc.
       3675 Market Street, Suite 200
       Philadelphia, PA 19104

                                                        Re: Context
Therapeutics Inc.
                                                            Amendment No. 4 to
Registration Statement on Form S-1
                                                            Filed September 13,
2021
                                                            File No. 333-256572

       Dear Mr. Lehr:

            We have reviewed your amended registration statement and have the
following
       comment.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comment applies to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to this comment, we may have additional comments.

       Amendment No. 4 to Registration Statement on Form S-1

       General

   1.                                                   We note that the
graphics following the prospectus cover page state that ONA-XR shows
                                                        efficacy supporting
continued development and addresses prior limitations of PRAs. We
                                                        also note your
statement on page 96 that tumor assessments in a Phase 2 trial indicated
                                                        ONA-XR anticancer
efficacy in heavily pretreated patients. Please revise these statements
                                                        to remove any
implication that ONA-XR is effective as determinations of efficacy are
                                                        solely within the
authority of the FDA or similar foreign regulators. You may present
                                                        clinical trial end
points and objective data resulting from trials without concluding
                                                        efficacy, and such
discussion is more appropriate in the Business section.

              You may contact Gary Newberry at 202-551-3761 or Kevin Vaughn at
202-551-3494 if
       you have questions regarding comments on the financial statements and
related matters. Please
 Martin Lehr
Context Therapeutics Inc.
September 22, 2021
Page 2

contact Ada D. Sarmento at 202-551-3798 or Tim Buchmiller at 202-551-3635 with
any other
questions.



                                                        Sincerely,
FirstName LastNameMartin Lehr
                                                        Division of Corporation
Finance
Comapany NameContext Therapeutics Inc.
                                                        Office of Life Sciences
September 22, 2021 Page 2
cc:       Ben A. Stacke, Esq.
FirstName LastName